|
1
|
Kamanger F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparties in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Inoue M and Tsugane S: Epidemiology of
gastric cancer in Japan. Postgrad Med J. 81:419–424. 2005.
View Article : Google Scholar
|
|
3
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glinelinus B, Ekstrom K, Hoffman K, Graf
W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom
H and Heuman R: Randomized comparison between chemotherapy plus
best supportive care with best supportive care in advanced gastric
cancer. Ann Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
MacDonald JS, Schein PS, Woolley PV,
Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet
R and Lagarde C: 5-Fluorouracil, doxorubicin, and mitomycin (fam)
combination chemotherapy for advanced gastric cancer. Ann Intern
Med. 93:533–536. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Findlay M, Cuningham D, Norman A, Mansi J,
Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter
R and Hill A: A phase II study in advanced gastro-esophageal cancer
using epirubicin and cisplatin in combination with continuous
infusion 5-fluorouracil (ECF). Ann Oncol. 5:609–616.
1994.PubMed/NCBI
|
|
7
|
Ohtsu A, Shimoda Y, Shirao K, Boku N,
Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S,
Fukuda H and Yoshida S: Randomized phase III trial of fluorouracil
alone vs. fluorouracil plus cisplatin vs uracil and tergafur plus
mitomycin in patients with unresectable, advanced gastric cancer:
the Japan Clinical Oncology Study (JCOG9205). J Clin Oncol.
21:54–59. 2003. View Article : Google Scholar
|
|
8
|
Koizumi W, Narahara H, Hara T, Takegane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin vs. S-1 alone for first-line treatment
of advanced gastric cancer (SPIRITS): A phase III trial. Lancet
Oncol. 9:215–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu
J and Ohtsu A: Gastrointestinal Oncology Study Group of the Japan
Clinical Oncology Group: Fluorouracil vs. combination of irinotecan
plus cisplatin vs S-1 in metastatic gastric cancer A randomized
phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Einzig AI, Neuberg D, Remick SC, Karp DD,
O’Dwyer PJ, Stewart JA and Benson AB 3rd: Phase II trial of
docetaxel (taxotere) in patients with adenocarcinoma of the upper
gastrointestinal tract previously untreated with cytotoxic
chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results
of protocol el293. Med Oncol. 13:87–93. 2006. View Article : Google Scholar
|
|
11
|
Thuss-Patience PC, Kretzchmar A and
Reichardt P: Docetaxel in the treatment of gastric cancer. Future
Oncol. 10:603–620. 2009.
|
|
12
|
Fushida S, Fujimura T, Oyama K, Yagi Y,
Kinoshita J and Ohta T: Feasibility and efficacy of preoperative
chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer
with para-aortic lymph node metastases. Anticancer Drug.
20:752–756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zang DY, Yang DH, Kim MJ, Jang KM, Hwang
SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, et al: Dose-finding
study of docetaxel, oxaliplatin, and S-1 for patients with advanced
gastric cancer. Cancer Chemother Pharmacol. 64:877–883. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshida K, Hirabayashi N, Takiyama W,
Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I
study of combination therapy with S-1 and docetaxel (TXT) for
advanced or recurrent gastric cancer. Anticancer Res. 24:1843–1851.
2004.PubMed/NCBI
|
|
15
|
Yoshida K, Ninomiya M, Takakura N,
Hirabayashi N, Takiyama W, Sato Y, Toda S, Terashima M, Gotoh M,
Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1
combination therapy for advanced gastric cancer. Clin Cancer Res.
12:3402–3407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim YH, Koizumi W, Lee KH, Kishimoto T,
Chung HC, Hara T, Cho JY, Nakajima T, Kim H and Fujii M: American
Society of Clininal Oncology – Gastrointestinal Symposium 2011,
Board #A8. J Clin Oncol. 29(Suppl 4): abs. 72011.
|
|
17
|
Eisenhauer EA, Terasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
18
|
Japanese Gastric Cancer Association.
Japanese classification of gastric carcinoma − 3rd English edition.
Gastric Cancer. 14:101–112. 2011.
|
|
19
|
Trotti A, Colevas AD, Setser A, Rusch H,
Jaques D, Budach V, Langer C, Murphy B, Cumberline R, Coleman CN
and Rubin P: CTCAC v3.0: development of a comprehensive grading
system for the adverse effects of cancer treatment. Semin Radiat
Oncol. 13:176–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lenz HJ, Lee FC, Haller DG, Singh D,
Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT and
Ajiani JA: Extended safety and efficacy data on S-1 plus cisplatin
in patients with untreated, advanced gastric carcinoma in a
multicenter phase II study. Cancer. 109:33–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SR, Kim HK, Kim CG, Choi IJ, Lee JS,
Lee JH, Ryu KW, Kim YW, Bae JM and Kim NK: Phase I/II study of S-1
combined with weekly docetaxel in patients with metastatic gastric
carcinoma. Br J Cancer. 98:1305–1311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki T, Tanabe K, Taomoto J, Yamamoto H,
Tokumoto N, Yoshida K and Ohdan H: Preliminary trial of adjuvant
surgery for advanced gastric cancer. Oncol Lett. 1:743–747.
2010.PubMed/NCBI
|
|
23
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Fukukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J M. 357:1810–1820. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kodera Y, Ishikawa A, Yoshikawa T,
Kinoshita T, Ito S, Yokoyama H, Michizuki Y, Ito H, Tsuburaya A,
Sakamoto J and Nakao A: A feasibility study of postoperative
chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma.
Gastric Cancer. 13:197–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fushida S, Fujimura T, Oyama K, Kinoshita
J, Fujita H, Ninomiya I and Ohta T: Neoadjuvant chemotherapy
combining docetaxel, cisplatin, and S-1 in gastric cancer with
para-aortic lymph node metastases: report of five cases.
Hepatogastroenterol. 57:1650–1654. 2010.PubMed/NCBI
|
